CD133 tended to be more highly expressed in cholangiocellular components of cHCC-CCA and in the intermediate cell type than in HCC areas (14.3% vs. 42.2%) and together with EpCAM expression profile has been shown to be associated with poor prognosis [143]. This evidence concerns the gene EPCAM and hepatocellular carcinoma.